הכנסה תפעולית לפני ניכוי פחת: codiagnostics.com (CODX)

The projected EBITDA level demonstrates operational efficiency dynamics, where 0.00 serves as the base parameter value. Co-Diagnostics, Inc. (CODX) is scaling the deployment of PCR systems through B2B contracts with laboratories to capture market share. Growth is driven by home platforms and tropical disease tests. High liquidity and stable cash flow completely offset financial risks associated with the creation of new products.

To minimize long-term capital risks, it is critical to monitor the slowing growth of real cash flow from operating activities, which this operational financial result clearly reflects. Since the success of Co-Diagnostics, Inc. (CODX) depends on the commercialization of developments and product cycles, analyzing the dynamics of profit before non-cash expenses allows for an assessment of business scaling efficiency and helps avoid purchasing the asset at its peak liquidity.